This phenotype implicates CDK6 as opposed to CDK4 for the poor prognosis of PDA in the clinic and questions the therapeutic benefits of Palbociclib in PDA therapy due to its synergistic effects on CDK4 and CDK6. The gene discussed is CDK4; the disease is Patent ductus arteriosus.